IOVS Journal of Neurophysiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hayashi, M.
Right arrow Articles by Bito, L. Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hayashi, M.
Right arrow Articles by Bito, L. Z.

Investigative Ophthalmology & Visual Science, Vol 28, 1639-1643, Copyright © 1987 by Association for Research in Vision and Ophthalmology

ARTICLES AND REPORTS

Eicosanoids as a new class of ocular hypotensive agents. 2. Comparison of the apparent mechanism of the ocular hypotensive effects of A and F type prostaglandins

M Hayashi, ME Yablonski and LZ Bito
Department of Ophthalmology, Columbia University College of Physicians and Surgeons, New York, New York 10032.

It has recently been shown that derived prostaglandins (PGs) of the A and B types are much more potent ocular hypotensive agents than primary PGs of the E, F, or D type. The purpose of this study was to determine whether two representatives of these structurally different PGs, namely PGA2 and PGF2 alpha-1-isopropyl ester (PGF2 alpha IE), reduce intraocular pressure (IOP) of the feline eye by similar or dissimilar mechanisms. Aqueous humor flow rate was determined by a fluorophotometric technique, Schiotz electronic tonography was used to measure outflow facility and venomanometry was done to measure episcleral venous pressure. Although at the doses used, both PGF2 alpha IE (2.5 micrograms/eye) and PGA2 (5.0 micrograms/eye) caused significant IOP reduction within 2.5 hr after their topical application, neither caused a significant decrease in aqueous humor flow rate, a significant increase in outflow facility or a change in episcleral venous pressure. It was concluded, therefore, that both of these PGs reduce IOP by an apparently similar mechanism, presumably by increasing uveoscleral outflow.


This article has been cited by other articles:


Home page
 Arch OphthalmolHome page
P. L. Kaufman
Prostaglandins and Cholinomimetics
Arch Ophthalmol, July 1, 1997; 115(7): 911 - 913.
[Abstract] [PDF]

Home page
 Arch OphthalmolHome page
N. Ziai, J. W. Dolan, R. D. Kacere, and R. F. Brubaker
The Effects on Aqueous Dynamics of PhXA41, a New Prostaglandin F2{alpha} Analogue, After Topical Application in Normal and Ocular Hypertensive Human Eyes
Arch Ophthalmol, October 1, 1993; 111(10): 1351 - 1358.
[Abstract] [PDF]

Home page
 Arch OphthalmolHome page
P. Racz, M. R. Ruzsonyi, Z. T. Nagy, and L. Z. Bito
Maintained Intraocular Pressure Reduction With Once-a-Day Application of a New Prostaglandin F2{alpha} Analogue (PhXA41) An In-Hospital, Placebo-Controlled Study
Arch Ophthalmol, May 1, 1993; 111(5): 657 - 661.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1987 by the Association for Research in Vision and Ophthalmology